印度医生报告,儿童镰状细胞病的干细胞移植非常成功,使用相亲兄弟姐妹的成功率高达96%。 Indian doctors report highly successful stem cell transplants for sickle cell disease in children, with up to 96% success using matched siblings.

在印度古鲁格拉姆福蒂斯纪念研究所的医生们报告说,根据对100个儿科病例进行的为期十年的研究,利用干细胞移植治疗镰状细胞疾病(SCD)儿童方面取得重大进展。 Doctors at Fortis Memorial Research Institute in Gurugram, India, report a major advance in curing children with Sickle Cell Disease (SCD) using stem cell transplants, based on a decade-long study of 100 pediatric cases. 该研究发表在Haemolobin上,发现总体存活率接近87%,其中96%成功进行配对的捐赠者移植手术,78%成功进行半匹配的家庭捐赠者移植手术,这是全球最好的。 The research, published in Haemoglobin, found an overall survival rate of nearly 87%, with 96% success in matched sibling donor transplants and 78% in half-matched family donor transplants—among the best globally. 该小组通过先进的规程取得了这些成果,这些规程减少了诸如移植寄生虫病等并发症,其中包括降低毒性的调节和移植后环磷酰胺。 The team achieved these outcomes through advanced protocols that reduce complications like graft-versus-host disease, including reduced-toxicity conditioning and post-transplant cyclophosphamide. 器官损害发生之前的早期干预是成功的关键。 Early intervention before organ damage occurred was key to success. 调查结果表明,在资源有限的情况下,高质量、可伸缩的干细胞移植是可行的,为印度和撒哈拉以南非洲儿童带来了希望,因为印度和撒哈拉以南非洲地区是性传染疾病最普遍的地区。 The findings demonstrate that high-quality, scalable stem cell transplants are feasible in resource-limited settings, offering hope for children in India and sub-Saharan Africa, where SCD is most prevalent. 专家们强调,需要捐助者登记册、早期诊断和强有力的移植后护理,以便在全世界扩大这种拯救生命的治疗。 Experts stress the need for donor registries, early diagnosis, and strong post-transplant care to expand access to this life-saving treatment worldwide.